Discontinued — last reported Q1 '25
Products & Services · Research and development funding expense
Litifilimab — Research and development funding expense
Analysis
StatementSegment
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2025May 8, 2025
Rolls up toR&D
How to read this metric
An increase reflects higher current-period investment in the asset's development, while a decrease may indicate reduced activity or the completion of specific clinical phases.
Detailed definition
This represents the actual cash or accrual-based expense recognized by the firm during the period to fund the research a...
Peer comparison
Comparable to R&D expense allocations or clinical development funding costs reported by pharmaceutical and biotech firms.
Metric ID:
rprx_segment_litifilimab_research_and_development_funding_expenseHistorical Data
1 periods
| Q1 '25 | |
|---|---|
| Value | $50.5M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's litifilimab — research and development funding expense?
- Royalty Pharma (RPRX) reported litifilimab — research and development funding expense of $50.5M in Q1 2025.
- What does litifilimab — research and development funding expense mean?
- The actual costs incurred by the company to fund Litifilimab research and development during the reporting period.